Endogenous nitric oxide synthesis under conditions of low oxygen tension
CA 2386938 A1 · Owner: Nitromed, Inc. · Inventors: Saenz De Tejada, Inigo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods of promoting synthesis of nitric oxide or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues by administering at least one N-hydroxyguanidine compound that is a substrate of nitric oxide synthase and at least one thromboxane inhibitor and, optionally, one or more vasoactive agents. The present invention also provides methods of promoting vasorelaxation and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compounds that is a substrate for nitric oxide synthase and at least one thromboxane inhibitor and, optionally, one or more vasoactive agents. The present invention also provides …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 26, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 26, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 26, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.